Legend Biotech Corporation announced that its subsidiary, Legend Biotech USA Inc., has entered into a Component and Product Supply Agreement with Janssen Pharmaceuticals, Inc. Under the agreement, Legend Biotech will manufacture and supply ciltacabtagene autoleucel (cilta-cel) for both clinical and commercial use outside Greater China. The product will be produced at the Raritan, New Jersey facility. Janssen will pay Legend Biotech a transfer price based on production costs plus a specified markup, with costs for commercial and clinical supply ultimately shared equally by both companies under an existing Collaboration Agreement. The agreement also outlines provisions relating to forecasts, ordering, delivery, payments, intellectual property, and other customary terms. The agreement will become effective after certain transition requirements and regulatory approvals are met, and will terminate if the Collaboration Agreement expires or is terminated.